The FDA’s 2004 black-box warning aimed to boost suicidality monitoring in youth on antidepressants. Two decades and thousands of prescriptions later, did it work—or did it quietly reshape treatment patterns in unintended ways?

Adult tapering rules don’t always translate cleanly to children and teens. A new systematic review asks which antidepressants carry the highest withdrawal risk in youth, and just how slow a taper needs to be.

Stimulant versus non-stimulant for ADHD is a familiar debate. A head-to-head trial looks beyond core symptoms to executive function and emotional side effects—where do the two agents diverge?

Avoidant/restrictive food intake disorder can stall despite months of good therapy, leaving weight and growth stuck. Could a low-dose atypical antipsychotic help these underweight, treatment-resistant youth finally turn the corner?

After reading these articles, you should be able to… 

Nonadherence affects roughly one-third of youth with severe mental illness—and those who need medication most are often least likely to take it. This update reviews the most common drivers of nonadherence, from forgetfulness and family dynamics to stigma and motivation, with practical strategies clinicians can apply at every visit.

The placebo effect is real, measurable, and often stronger in children than adults, yet it’s routinely underused. This update explains the neurobiology behind placebo response, how "placebo by proxy" shapes outcomes through caregiver expectations, and how to use open-label placebo approaches ethically and effectively in everyday clinical practice.